Dr Rosalind Hannen is the Founder and CEO of Keratify. She completed her BBSRC-Unilever PhD studentship in dermatoendocrinology at the Blizard Institute, Queen Mary University of London (QMUL) in 2009 and actively created all her subsequent postdoctoral research positions by personally writing and winning grant funding, pitching to businesses and engaging in all types of funding opportunities.
She won the British Skin Foundation grant award in 2016 to further her research in psoriasis and was awarded a MedCity grant (the highest ranked grant) in 2017 with Fourth State Medicine to assess the effectiveness of plasma technology for chronic wound healing. In 2018, Ros won the MedTech SuperConnector and QMUL Life Sciences Initiative awards to accelerate the commercial development of her research; and most recently an Innovate UK Smart grant. Ros founded Keratify in December 2018 to advance laboratory human skin testing.
Her talk about research commercialisation will take place on 26th March 2021 at 11:15am GMT.